This poster presents the development of a robust, automated iPSC-derived neuronal screening platform for early efficacy and neurotoxicity assessment of RNA therapeutics, designed to operate reliably at scale in discovery environments.
Download it now for a closer look at:
How fully automated, liquid-handling–based workflows enable reproducible ASO screening from cell seeding through RT-qPCR and functional readouts
Assay performance data showing low intra- and inter-plate variability below five percent, supporting reliable decision-making across screening campaigns
Human-relevant neurotoxicity assessment using calcium imaging and MEA to functionally discriminate between safe and toxic ASOs early in discovery
Why integrating automation, standardized protocols, and iPSC-derived neuronal models reduces operational risk and improves throughput consistency
Whether supporting early candidate triage or scaling RNA screening programs, Ncardia’s iPSC-derived neuronal platforms provide a reproducible and automated foundation for human-relevant decision-making early in the pipeline.